PP
RPRX

Paloma Partners’s Repros Therapeutics Inc. RPRX Stock Holding History

Paloma Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-37,400
Closed -$267K – 2317
2015
Q2 		$267K Buy
+37,400
New +$291K 0.01% 1396
2015
Q1 		– Sell
-35,581
Closed -$355K – 1646
2014
Q4 		$355K Buy
+35,581
New +$303K 0.02% 793
2014
Q2 		– Sell
-14,580
Closed -$259K – 1375
2014
Q1 		$259K Buy
+14,580
New +$282K 0.02% 533

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return

Paloma Partners's RPRX Position: Q3 2015 in Review

Paloma Partners sold out of Repros Therapeutics Inc. (RPRX) in Q3 2015, closing a stake of 37,400 shares — an estimated $267K sold.

Paloma Partners first reported a position in RPRX in Q1 2014 and held it in 3 quarters. The position peaked at $355K in Q4 2014. 58 funds tracked by Wall St. Rank hold RPRX as of Q3 2015.

  • Paloma Partners reported no remaining Repros Therapeutics Inc. position as of Q3 2015 after selling out during the quarter.
  • Paloma Partners sold 37,400 Repros Therapeutics Inc. shares in Q3 2015, an estimated $267K.
  • Paloma Partners first reported a position in Repros Therapeutics Inc. in Q1 2014 and held it in 3 quarters.
  • Paloma Partners's Repros Therapeutics Inc. position peaked at $355K in Q4 2014.
  • 58 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2015.

Based on Paloma Partners's 13F filing for Q3 2015, filed 16 Nov 2015.